This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

electroCore, Inc.
11/4/2026
Greetings, and welcome to the ElectroCore third quarter, 2026 earnings conference call. At this time, all participants have been placed in listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Earlier today, ElectroCore published results for the third quarter, and it's September 30th, 2026, and the press release is available on the company's website. Before we begin, I would like to remind everyone that members on the call will make forward-looking statements within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical facts should be deemed to be forward-looking, including without limitation any guidance to companies' outlook on fourth quarter and full-year performance and its path to profitability. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated. For a list of risk factors, please see the company's filings with the Securities and Exchange Commission, including but not limited to the current report on 8K and Form 10Q filed today with the SEC. ElectroCore disclaims any obligation to update these statements, except as required by law. This call contains time-sensitive information, accurate only as of today, November 4, 2026. Joining us on today's call from ElectroCore are Dr. Thomas Errico, one of the company's founders, investor, and independent chairman of the board of directors, Joshua Lev, co-chief executive officer, president, and chief financial officer, and Mike Fox, co-chief executive officer, president, and chief operating officer. It is now my pleasure to turn the call over to Dr. Thomas Errico, ElectroCore's founder and independent chairman, for opening remarks. Dr. Errico?
Thank you, operator. Good afternoon, everyone, and thank you for joining Electric Core's third quarter 2026 earnings call. This quarter was about strengthening the foundation, leadership, commercial execution, and regulatory clarity. The results strengthened my conviction and excitement about the company's current trajectory. This was a record quarter for Electric Core, our highest net sales and our smallest operating loss in company history. Behind those results, management is building a commercial organization designed to grow profitably at a much larger scale. As with any transformation, the changes have been significant, and we believe the changes we have executed have established a foundation that positions Electric Core for accelerated growth and an inflection point in positive adjusted EBITDA in 2027. For me, one of the most exciting developments is our progress opening new markets. On October 27th, we filed our 510K pre-market notification with the FDA seeking clearance for our Quell Wearable Neurostimulation Device for the treatment of chemotherapy-induced peripheral neuropathy, or CIPN. This submission comes on the back of the breakthrough designation from the FDA in January 2022. which covers the reduction of moderate to severe symptoms of chemotherapy-induced peripheral neuropathy that have persisted for at least six months after chemotherapy ended. If cleared, Quell could offer a new non-drug option for patients experiencing CIPN, an important step for ElectroCore and those patients looking for symptom relief. Combined with continued progress in commercial execution and financial discipline, this new opportunity shows the path forward is stronger today than at any point in the last several years. Josh will take you through the quarter and where we are headed. Mike will walk you through the plans implemented for growth and measures we track in the field. And Josh will then return with the financials. Josh.
Thank you, Tom. Good afternoon, everyone. This quarter, we delivered record net sales of $9.7 million, up approximately 12% from a year ago, and the lowest operating loss in our history, with adjusted EBITDA loss improving by nearly $1.4 million in the quarter, ahead of our expectations. Gross margin expanded to 88.5%, and loss from operation narrowed to $1.6 million. Gap net loss improved by $1.3 million or 13 cents per share from $3.1 million or 33 cents per share in the second quarter and adjusted EBITDA loss improved to a company record $700,000. We grew revenue while spending less to do it. I will take you through the full financials later in the call. I want to be direct about where we are taking this company. We are not managing for short-term gains. We are building long-term revenue that is durable, repeatable, and profitable. Every decision we made this year was made on purpose, knowing it could cost us near-term growth for longer-term success and profitability. Truvega is the clearest example. Direct-to-consumer Truvega revenue was down from a year ago and that is exactly what we intended. The number of competitors bidding on Truevega's own branded search term is up 60% and our cost per click is up roughly 42%. We could have kept spending to grow the top line, but it would have been empty calorie revenue, padding the revenue line while pushing us further from profitability. So we chose not to chase it and our return on advertising spend improved 8% year over year. This represents how we think about driving revenue, not just driving the top line, but doing it with profitability in mind. The improvement in our P&L is the early proof that this approach works. Net sales are up, operating expenses are down, and the company that grows while spending less is a company getting stronger. On guidance, we are revising our full year 2026 revenue outlook to $39 to $42 million from our prior guidance of greater than 30% year-over-year growth. This is a change in timing, not direction. The sales organization changes we made are taking longer to reach the full field than we planned. So the acceleration we expected in the second half of 2026, we now expect in 2027. We made those changes because they are right for the business. That brings me to why we are confident in 2027. It comes down to three themes. First, coverage. More staffed VA accounts means more facilities where a representative is in the building selling both Gamma Core and Quell. Second, accountability. Smaller territories give every account a clear owner and a clear standard for results. Third, Early proof that the model works. Mike will walk you through the leading indicators in the field, including how the representatives we have added since June are producing more revenue from their accounts than those accounts generated before they arrived. In addition, our chemotherapy-induced peripheral neuropathy, or CIPN, 510K is under FDA review. If we receive clearance in 2027, we could grow QWEL revenue in two ways. by making sure reps are carrying Quell across our entire coverage area and by opening a new indication for chemotherapy-induced peripheral neuropathy where, to our knowledge, there is currently no medical device or pharmaceutical alternative specifically indicated for CIPM. We believe these improvements will help us to deliver accelerated revenue growth in the full year 2027 with preliminary 2027 new growth guidance of 30 to 40% year over year. And we expect to refine this guidance range and provide additional commentary as appropriate in the future. Similar to what we discussed last quarter and based on our current model, if we achieve that growth, we currently believe the operating leverage in our model with gross margins in the upper 80s on a streamlined cost base along with our existing cash on hand and financing resources positions us to achieve our first fiscal quarter of positive adjusted EBITDA by the end of 2027 without entering into a new dilutive equity capital financing transaction. The next 12 months are about execution and I would like Mike to show you how we are going to do that. Mike?
You're reading a preview of the ECOR Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing